ADX-102 1% Topical Dermal Cream (reproxalap) ( DrugBank: Reproxalap )


1 disease
IDDisease name (Link within this page)Number of trials
160Congenital ichthyosis1

160. Congenital ichthyosis


Clinical trials : 36 Drugs : 72 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03445650
(ClinicalTrials.gov)
July 18, 201814/2/2018RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)Sjogren-Larsson SyndromeDrug: ADX-102 1% Topical Dermal Cream (reproxalap);Drug: Vehicle of ADX-102 Topical Dermal CreamAldeyra Therapeutics, Inc.NULLCompleted3 YearsN/AAll11Phase 3United States